
89bio Inc (ETNB) Stock Forecast & Price Target
89bio Inc (ETNB) Analyst Ratings
Bulls say
89bio Inc is positioned favorably within the clinical-stage biopharmaceutical landscape due to its innovative product candidate, pegozafermin, which targets significant unmet medical needs in liver and cardio-metabolic diseases, particularly nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company's recent financial reports indicate a solid cash position and prudent spending, allowing for sustained development efforts without immediate dilution risks. Additionally, the promising results from clinical trials for pegozafermin suggest a strong potential market impact, enhancing investor confidence in the company's growth trajectory.
Bears say
89bio Inc faces significant risks that contribute to a negative outlook on its stock performance. Key concerns include the potential failure of its product candidate, pegozafermin, to meet commercial revenue expectations due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may encounter difficulties securing necessary capital resources to support ongoing operational and developmental initiatives, which poses a further threat to its financial stability and growth prospects.
This aggregate rating is based on analysts' research of 89bio Inc and is not a guaranteed prediction by Public.com or investment advice.
89bio Inc (ETNB) Analyst Forecast & Price Prediction
Start investing in 89bio Inc (ETNB)
Order type
Buy in
Order amount
Est. shares
0 shares